BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables
BioHarvest Sciences Appoints Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables
Experienced Life Sciences Executive to Support Cosmeceuticals and Injectables Growth for New CDMO Business Unit
經驗豐富的生命科學高管將支持新的CDMO業務部門的藥妝品和注射劑的增長
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 21, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the appointment of experienced life sciences executive Anna Tenstam as VP of Business Development, Cosmeceuticals and Injectables, to drive broader expansion of the Company's recently launched Contract Development and Manufacturing Organization ("CDMO") Services Business Unit.
不列顛哥倫比亞省溫哥華和以色列雷霍沃特--（Newsfile Corp.，2024年3月21日）——開創其專利植物合成技術平台的生物技術公司BioHarvest Sciences Inc.（CSE：BHSC）（OTCQB：CNVCF）（“BioHarvest” 或 “公司”）今天宣佈任命經驗豐富的生命科學高管安娜·滕斯塔姆爲藥妝品和注射劑業務開發副總裁推動公司最近成立的合同開發和製造組織（“CDMO”）服務業務部門的更廣泛擴張。
"Anna's business development acumen - paired with her extensive experience in life sciences - presents an incredible opportunity to accelerate our business with pharmaceutical, cosmeceutical, nutraceutical and nutrition industry leaders," said Ilan Sobel, Chief Executive Officer of BioHarvest Sciences. "Her invaluable relationships with global industry partners within these industries positions BioHarvest to attract development and long-term manufacturing contracts for our CDMO business unit. We look forward to working closely with Anna going forward as we continue to successfully scale operations, all with the goal of creating sustainable value for my fellow shareholder partners over the long-term."
BioHarvest Sciences首席執行官伊蘭·索貝爾表示：“安娜的業務發展敏銳度，加上她在生命科學領域的豐富經驗，爲加快與製藥、藥品、營養品和營養行業領導者的業務發展提供了難得的機會。”“她與這些行業的全球行業合作伙伴的寶貴關係使BioHarvest能夠爲我們的CDMO業務部門吸引開發和長期製造合同。在我們繼續成功擴大運營規模的過程中，我們期待與Anna密切合作，所有目標都是爲我的股東合作伙伴創造長期可持續的價值。”
Anna Tenstam
安娜·滕斯塔姆
Anna Tenstam has over 30 years of leadership experience with pharmaceutical, medical devices and medical aesthetics companies worldwide, holding executive positions in several global companies in these industries. She has managed global brands and been involved in several license and exit deals with companies such as Colbar Lifescience/J&J, and Q-MED/Medicis/Galderma, among others. She currently serves on the Board of Daya Ventures, Oxagon AB, Medicortex Finland Oy and Optomed Plc, Finland. She holds an MSc from Uppsala University and an MBA from IMD Lausanne.
Anna Tenstam 在全球製藥、醫療器械和醫學美容公司擁有超過 30 年的領導經驗，曾在這些行業的多家跨國公司擔任高管職務。她曾管理過全球品牌，並參與了與Colbar Lifescience/J＆J和Q-med/Medicis/Galderma等公司的多項許可和退出協議。她目前在Daya Ventures、Oxagon AB、芬蘭Medicortex Oy和芬蘭Optomed Plc的董事會任職。她擁有烏普薩拉大學的碩士學位和洛桑IMD的工商管理碩士學位。
Tenstam commented: "I am truly privileged to join the team at BioHarvest, and excited to focus on building partnerships with industry leaders who are searching for the next generation of therapeutic molecules. My chief focus at BioHarvest will be to uncover new opportunities within cosmeceuticals and injectables, with the goal of building revenues for the CDMO services business unit."
Tenstam評論說：“我很榮幸能加入BioHarvest的團隊，也很高興能專注於與正在尋找下一代治療分子的行業領導者建立合作伙伴關係。我在BioHarvest的主要重點將是發現藥妝和注射劑領域的新機會，目標是爲CDMO服務業務部門創造收入。”
About BioHarvest Sciences Inc.
BioHarvest 科學公司簡介
BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit .
BioHarvest Sciences Inc.（CSE：BHSC）（場外交易代碼：CNVCF）（FSE：8MV）是植物合成領域的領導者，利用其專利技術平台培育植物基分子，無需種植底層植物。BioHarvest正在利用其植物合成技術在兩個主要垂直業務領域開發基於科學且經過臨床驗證的下一代治療解決方案；作爲代表尋求複雜分子的客戶的合同開發和生產組織（CDMO），以及作爲專有營養保健品健康和保健產品（包括膳食補充劑）的創造者。要了解更多信息，請訪問。
Forward-Looking Statements
前瞻性陳述
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements.. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
本新聞稿中提供的信息可能包括基於管理層當前估計、信念、意圖和預期的前瞻性陳述，並且存在許多風險和不確定性，這些風險和不確定性可能導致實際業績與前瞻性陳述中描述的結果存在重大差異。所有前瞻性陳述本質上都是不確定的，實際結果可能會受到我們無法控制的許多重大因素的影響。讀者不應過分依賴前瞻性陳述。除了通過我們的定期管理層討論和分析披露外，BHSC無意更新前瞻性陳述披露。
Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其監管服務提供商均不對本新聞稿的充分性或準確性承擔責任。
This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibility for its contents.
本新聞稿已由投資者關係副總裁戴夫·瑞安審查和批准，他對其內容承擔責任。
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations & Director
+1 (604) 622-1186
info@bioharvest.com
BioHarvest 公司聯繫方式
投資者關係副總裁兼董事戴夫·瑞安
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHSC@mzgroup.us
投資者關係聯繫人：
盧卡斯·A·齊默爾曼
董事總經理
MZ 集團-MZ 北美
+1 (949) 259-4987
BHSC@mzgroup.us
譯文內容由第三人軟體翻譯。